Literature DB >> 19531654

Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer.

Koichi Matsuzaki1, Chiaki Kitano, Miki Murata, Go Sekimoto, Katsunori Yoshida, Yoshiko Uemura, Toshihito Seki, Shigeru Taketani, Jun-ichi Fujisawa, Kazuichi Okazaki.   

Abstract

Transforming growth factor (TGF)-beta initially inhibits growth of mature epithelial cells. Later, however, autocrine TGF-beta signaling acts in concert with the Ras pathway to induce a proliferative and invasive phenotype. TGF-beta activates not only TGF-beta type I receptor (TbetaRI) but also Ras-associated kinases, which differentially phosphorylate the mediators Smad2 and Smad3 to create distinct phosphorylated forms: COOH-terminally phosphorylated Smad2/3 (pSmad2C and pSmad3C) and both linker and COOH-terminally phosphorylated Smad2/3 (pSmad2L/C and pSmad3L/C). In this study, we investigated actions of pSmad2L/C and pSmad3L/C in cancer progression. TGF-beta inhibited cell growth by down-regulating c-Myc oncoprotein through the pSmad2C and pSmad3C pathway; TGF-beta signaling, in turn, enhanced cell growth by up-regulating c-Myc through the cyclin-dependent kinase (CDK) 4-dependent pSmad2L/C and pSmad3L/C pathways in cell nuclei. Alternatively, TbetaRI and c-Jun NH2-terminal kinase (JNK) together created cytoplasmic pSmad2L/C, which entered the nucleus and stimulated cell invasion, partly by up-regulating matrix metalloproteinase-9. In 20 clinical samples, pSmad2L/C and pSmad3L/C showed nuclear localization at invasion fronts of all TGF-beta-producing human metastatic colorectal cancers. In vitro kinase assay confirmed that nuclear CDK4 and cytoplasmic JNK obtained from the tumor tissue could phosphorylate Smad2 or Smad3 at their linker regions. We suggest that CDK4, together with JNK, alters tumor-suppressive TGF-beta signaling to malignant characteristics in later stages of human colorectal cancer. The linker phosphorylation of Smad2 and Smad3 may represent a target for intervention in human metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531654     DOI: 10.1158/0008-5472.CAN-08-4203

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  Release the ink4a/arf growth suppression by "u" and "me"?

Authors:  Shuo Qie; Nianli Sang
Journal:  Cell Cycle       Date:  2011-01-15       Impact factor: 4.534

2.  The prognostic significance of Smad3, Smad4, Smad3 phosphoisoform expression in esophageal squamous cell carcinoma.

Authors:  Soo Youn Cho; Sang Yun Ha; Song-Mei Huang; Jeong Hoon Kim; Myung Soo Kang; Hae-Yong Yoo; Hyeon-ho Kim; Cheol-Keun Park; Sung-Hee Um; Kyung-Hee Kim; Seok-Hyung Kim
Journal:  Med Oncol       Date:  2014-09-30       Impact factor: 3.064

3.  MAPK inhibitors differently modulate TGF-β/Smad signaling in HepG2 cells.

Authors:  A Boye; H Kan; C Wu; Y Jiang; X Yang; S He; Y Yang
Journal:  Tumour Biol       Date:  2015-01-07

Review 4.  Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases.

Authors:  Takashi Yamaguchi; Katsunori Yoshida; Miki Murata; Koichi Matsuzaki
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

5.  Single Chain Antibodies as Tools to Study transforming growth factor-β-Regulated SMAD Proteins in Proximity Ligation-Based Pharmacological Screens.

Authors:  Andries Blokzijl; Agata Zieba; Michael Hust; Thomas Schirrmann; Saskia Helmsing; Karin Grannas; Ellen Hertz; Anita Moren; Lei Chen; Ola Söderberg; Aristidis Moustakas; Stefan Dübel; Ulf Landegren
Journal:  Mol Cell Proteomics       Date:  2016-02-29       Impact factor: 5.911

6.  Phosphorylation of Smad2/3 at specific linker threonine indicates slow-cycling intestinal stem-like cells before reentry to cell cycle.

Authors:  Masanobu Kishimoto; Toshiro Fukui; Ryo Suzuki; Yu Takahashi; Kimi Sumimoto; Takashi Okazaki; Masayuki Sakao; Yutaku Sakaguchi; Katsunori Yoshida; Kazushige Uchida; Akiyoshi Nishio; Koichi Matsuzaki; Kazuichi Okazaki
Journal:  Dig Dis Sci       Date:  2014-09-04       Impact factor: 3.199

7.  TGF-β-activated kinase 1 (Tak1) mediates agonist-induced Smad activation and linker region phosphorylation in embryonic craniofacial neural crest-derived cells.

Authors:  Kenji Yumoto; Penny S Thomas; Jamie Lane; Kouichi Matsuzaki; Maiko Inagaki; Jun Ninomiya-Tsuji; Gregory J Scott; Manas K Ray; Mamoru Ishii; Robert Maxson; Yuji Mishina; Vesa Kaartinen
Journal:  J Biol Chem       Date:  2013-04-01       Impact factor: 5.157

8.  Increased cell migration and plasticity in Nrf2-deficient cancer cell lines.

Authors:  G Rachakonda; K R Sekhar; D Jowhar; P C Samson; J P Wikswo; R D Beauchamp; P K Datta; M L Freeman
Journal:  Oncogene       Date:  2010-05-03       Impact factor: 9.867

9.  Pin1 promotes transforming growth factor-beta-induced migration and invasion.

Authors:  Isao Matsuura; Keng-Nan Chiang; Chen-Yu Lai; Dongming He; Guannan Wang; Romila Ramkumar; Takafumi Uchida; Akihide Ryo; Kunping Lu; Fang Liu
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

10.  SKI knockdown inhibits human melanoma tumor growth in vivo.

Authors:  Dahu Chen; Qiushi Lin; Neil Box; Dennis Roop; Shunsuke Ishii; Koichi Matsuzaki; Tao Fan; Thomas J Hornyak; Jon A Reed; Ed Stavnezer; Nikolai A Timchenko; Estela E Medrano
Journal:  Pigment Cell Melanoma Res       Date:  2009-12       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.